About us

Shenyang Hongqi Pharmaceutical Co., Ltd. was founded in 1964. Since the 1980s, it has focused on the R&D, production, sales and service of anti tuberculosis drugs. After more than three decades of unremitting efforts, it has provided high-quality drugs and services to more than 15 million tuberculosis patients. In 2010, Hongqi Pharmaceutical became a member enterprise of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Hongqi Pharmaceutical, with the mission of "letting people no longer suffer from tuberculosis" and the vision of "creating an international first-class anti tuberculosis drug pharmaceutical enterprise", adheres to innovation leading development and increases R&D investment year by year. In 2022, R&D investment will account for 13.6% of the company's sales revenue. As the medical transformation innovation base of China Anti TB Association, the innovative drug research and development base of Shenzhen National infectious diseases Clinical Medical Research Center, the enterprise technology center of Liaoning Province, and the innovative achievement transformation project unit of Liaoning Province, we continue to deepen the scientific and technological innovation and medical research and development fields, focus on patients, and comprehensively help the cause of tuberculosis prevention and control in China.

In recent years, Hongqi Pharmaceutical has successively introduced rifampicin freeze-dried powder injection, isoniazid injection, linezolid tablets and other products, and developed a new domestic drug PA-824, bringing more drug choices for tuberculosis patients.

Hongqi Pharmaceutical has built a new tuberculosis drug production line in accordance with WHO PQ standards, improving product quality and production capacity, and can meet the needs of over 5 million patients. Simultaneously conducting consistency evaluations of multiple major product quality and efficacy, as well as WHO PQ certification, all first-line anti-tuberculosis drugs have passed the consistency evaluation of generic drugs. Among them, pyrazinamide tablets, isoniazid tablets (0.3g), and rifampicin capsules (0.3g) are the first approved drugs in China.

The anti tuberculosis series drugs produced and under research by Hongqi Pharmaceutical cover more than 90% of the drugs, covering the key drugs for the treatment of sensitive and drug-resistant tuberculosis. Hongqi Pharmaceutical also actively promotes the localization and innovation of second-line anti tuberculosis drugs, based on domestic and global perspectives, and contributes to the realization of the goal of ending the epidemic of tuberculosis.

In response to the call of the state, in 2016, Hongqi Pharmaceutical raised funds to build the Anti TB Drug Supply Coordination Reserve of China Anti TB Association, effectively ensuring the supply of first-line anti TB drugs in China and meeting the national needs for tuberculosis prevention and control. At the beginning of 2016, Hongqi Pharmaceutical and Fosun Foundation and China Anti TB Association jointly launched the "Double Thousand" relief project for poor tuberculosis patients. The project lasted for five years, with a total investment of 5 million yuan, covering 31 provinces, cities and autonomous regions, and providing relief to more than 5300 poor tuberculosis patients nationwide. In May 2017, Hongqi Pharmaceutical and the tuberculosis Diagnosis and Treatment Innovation Alliance jointly launched the "Young Eagle" project, aiming to cultivate more young talents in the field of tuberculosis treatment. As the standing director unit of China Anti TB Association and the director unit of tuberculosis Diagnosis and Treatment Innovation Alliance in Beijing, Hongqi Pharmaceutical will play an active and important role in the prevention and treatment of tuberculosis. In 2017, Hongqi Pharmaceutical was awarded the titles of Shenyang Science and Technology Little Giant Enterprise and Shenyang High tech Enterprise in Liaoning Province. In 2018, Chairman Yang Bo was named one of the first 100 most beautiful anti tuberculosis individuals in China, and Hongqi Pharmaceutical was awarded the title of China's AAA level credit enterprise. In 2019 and 2021, Hongqi Pharmaceutical was awarded the title of Top 100 Private Enterprise Technology Innovation in Shenyang. In December 2021, Hongqi Pharmaceutical and China Anti TB Association jointly launched the "Double Health" project, which aims at public health education and health personnel training for tuberculosis. The project will be implemented for five years with a support fund of 5 million yuan. It is estimated that 2500 drug-resistant TB patients will be cared for and 5000 health education will be conducted in the five years from 2022 to 2027.

In the future, Hongqi Pharmaceutical will also rely on the construction of the Hainan platform, deeply cultivate the urology and andrology product line, build production and sales capabilities, and become an important component of Fosun's "health, happiness, and abundance" happy life in the urology and andrology field, and become a high-quality supplier of domestic happy life product groups.